Perfeziona i miei risultati
Document type
Institution
Collection spécifique
Lingua
- Inglese (2)
Autore
-
Di Mitri, Diletta (2)
- Alimonti, Andrea (1)
- Avolio, Carlo (1)
- Battistini,Luca (1)
- Bergami, Alessandra (1)
- Borsellino, Giovanna (1)
- Catapano, Carlo V. (1)
- Centonze, Diego (1)
- Civenni, Gianluca (1)
- Comi, Giancarlo (1)
- Dalla Libera, Dacia (1)
- Furlan, Roberto (1)
- Galgani, Simona (1)
- Garcia-Escudero, Ramon (1)
- Gasperini, Claudio (1)
- Grassi, Fabio (1)
- Grasso, Maria Grazia (1)
- Guccini, Ilaria (1)
- Jarrossay, David (1)
- Kalathur, Madhuri (1)
- Marini, Camilla (1)
- Martinelli, Vittorio (1)
- Martino, Gianvito (1)
- Montani, Erica (1)
- Pandolfi, Pier Paolo (1)
- Pinton, Sandra (1)
- Proietti, Michele (1)
- Revandkar, Ajinkya (1)
- Sallusto, Federica (1)
- Sarti, Manuela (1) Di più Meno
Parola chiave
- Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However (1)
- activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in Pten-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2 (1)
- in Pten-null senescent tumors (1)
- providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly (1)
- these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments. (1)
- this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein (1)
- treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in Pten-null tumors. Altogether (1)
- we report that (1)